Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate,AIDS Research and Human Retroviruses

当前位置： X-MOL 学术 › AIDS Res. Hum. Retrovir. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate
AIDS Research and Human Retroviruses ( IF 1.5 ) Pub Date : 2022-12-12 , DOI: 10.1089/aid.2022.0044
Jenna Yager ₁ , Kristina M Brooks ₁ , Jennifer Brothers ₂ , Kathleen Mulligan ₃ , Raphael J Landovitz ₄ , Daniel Reirden ₅ , Meenakshi Malhotra ₂ , Carrie Glenny ₅ , Paul Harding ₆ , Tina Powell ₆ , Peter L Anderson ₁ , Sybil Hosek ₂

Affiliation

Transgender persons have an increased vulnerability to HIV infection yet have not been well-represented in past clinical trials for pre-exposure prophylaxis (PrEP). Because of this, there are few data available to understand whether gender-affirming hormone concentrations are influenced by PrEP agents in transgender men (TM) and transgender women (TW). The objective of this study was to compare gender-affirming hormone concentrations with versus without emtricitabine (F, FTC)–tenofovir disoproxil fumarate (TDF). TM and TW without HIV, aged 15–24 years, were enrolled for 1 month of directly observed daily F/TDF. Participants were required to be receiving a stable hormone dose (estradiol or testosterone) for at least 1 month or three consecutive doses, whichever was longer, before enrollment and willing to continue the same dose. Intensive pharmacokinetic (PK) sampling for gender-affirming hormones was collected before and 2–3 weeks after daily F/TDF. Serum estradiol and total testosterone were determined by liquid chromatography–tandem mass spectrometry; free testosterone by equilibrium dialysis. Maximum concentrations (C_max) and area under the curve (AUC_last) were log-transformed and compared between baseline and on F/TDF using geometric mean ratios (GMRs) with 95% confidence intervals (CIs). Twenty-five TW and 24 TM were enrolled (median age: 20 and 21 years, respectively). In TW, estradiol C_max (GMR [95% CI]: 0.85 [0.65–1.11]) and AUC_last (GMR [95% CI]: 0.87 [0.73–1.03]) were comparable on F/TDF versus baseline. In TM, similar comparability was observed for PrEP versus baseline including total testosterone C_max (GMR [95% CI]: 0.91 [0.80–1.03]) and AUC_last (GMR [95% CI]: 0.91 [0.81–1.04]) and free testosterone C_max (GMR [95% CI]: 0.89 [0.74–1.07]) and AUC_last (GMR [95% CI]: 0.88 [0.74–1.03]). Estradiol and testosterone exposures in young TW and TM did not significantly differ on F/TDF versus baseline. These findings should reassure patients and providers that F/TDF can be used as PrEP without concern for altering gender-affirming hormone PK. ClinicalTrials.gov (NCT03652623).

更新日期：2022-12-14

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11